ArticleNeoplasia (New York, N.Y.)2006
Endothelin receptor A blockade enhances taxane effects in prostate cancer.
Article in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.The Lancet. Oncology · 2013Trial
- Trial
- Repurposing of the Drug Tezosentan for Cancer Therapy.Current issues in molecular biology · 2023Review
- Salvianolic Acid A, as a Novel ETA Receptor Antagonist, Shows Inhibitory Effects on Tumor in Vitro.International journal of molecular sciences · 2016Article
- Bone-targeting agents in prostate cancer.Cancer metastasis reviews · 2014Review
- Endothelin 1 in cancer: biological implications and therapeutic opportunities.Nature reviews. Cancer · 2013Review
- Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.Translational oncology · 2012Article
- Emerging targeted therapies for castration-resistant prostate cancer.Frontiers in endocrinology · 2012Article
- The PCa Tumor Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
- Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.Neoplasia (New York, N.Y.) · 2011Article
- Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.PloS one · 2011Article
- From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.Clinical & developmental immunology · 2011Review
- Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?Cancer biology & therapy · 2010Article
- Endothelin B receptor, a new target in cancer immune therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Review
- Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.Breast cancer research : BCR · 2009Article
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
- Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors.Current oncology reports · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ET(A)) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact of the combination of the ET(A) antagonist atrasentan (ABT-627) and taxane chemotherapy on prostate cancer cell survival in vitro and on the delay of prostate cancer in a xenograft mouse model. In vitro, PPC-1 cells transfected with an ET(A)-overexpressing vector were treated with ABT-627, paclitaxel/docetaxel, or both. Clonogenic viability and cell death assays were used to determine cell survival and apoptosis, respectively. ABT-627 and docetaxel combination treatment was used in vivo to treat mice with established ET(A)-overexpressing PPC-1 xenograft tumors, and tumor growth rates were assessed. Cell proliferation and vascularity were determined with Ki-67 and CD31 staining, respectively. Cells treated with combination therapy had significantly fewer viable cells and more programmed cell death than cells given monotherapy. Xenograft tumor growth rates were significantly lower in mice treated with combination therapy than in animals given a single agent. Ki-67 immunostaining demonstrated significantly fewer proliferative cells following combination therapy than following monotherapy. This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.